This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Epigenetic Therapies And Technologies: World Market Prospects 2013-2023

10. Research Interviews

10.1 Dr James Rusche, SVP R&D, Repligen

10.1.1 The Advantage in Using HDAC Inhibitors

10.1.2 Combination Therapy Using HDAC Inhibitors

10.1.3 Challenges in Developing Epigenetic Drugs

10.1.3.1 Challenges Specific to Selective HDAC Inhibitors

10.1.4 Partnering for Epigenetic Drug Development

10.2 Dr Simon Kerry, CEO, Karus Therapeutics

10.2.1 Differences in Developing Selective and pan-HDAC Inhibitors

10.2.2 HDAC Inhibitors for Cancer and Other Diseases

10.2.3 Comparison of Kinase Inhibitor and HDAC Inhibitor Development

10.2.4 The Future of Epigenetic R&D

11. Conclusions from Our Study

11.1 Drugs Account for Most Epigenetic Revenues in 201211.2 Growth Expected in All Sectors of the Epigenetics Market 2013-202311.2.1 Developed Markets to Dominate 2013-202311.3 Many Opportunities Exist for Market Entry

List of Tables

Table 1.1 Currency Exchange Rates, 2011

Table 2.1 Selected Enzymes Involved in Epigenetic Mechanisms

Table 2.2 Selected Treatments for MDS, 2012

Table 3.1 Epigenetic Therapies and Technologies Market by Sector, 2011

Table 3.2 Epigenetic Therapies and Technologies Market: Overall Market and Revenue Forecasts by Sector, 2011-2023

Table 3.3 Epigenetic Therapies and Technologies Market: Drivers and Restraints, 2013-2023

Table 3.4 Epigenetic Therapies and Technologies Submarket Shares, 2011-2023

Table 3.5 Epigenetic Therapies Submarket by Drug, 2011

Table 3.6 Epigenetic Therapies Submarket: Overall Submarket and Revenue Forecasts by Drug, 2011-2023

Table 3.7 Epigenetic Therapies Submarket: Drivers and Restraints, 2013-2023

Table 3.8 Epigenetic Technologies Submarket: Revenue Forecast, 2011-2023

Table 3.9 Epigenetic Technologies Submarket: Drivers and Restraints, 2013-2023

Table 3.10 Epigenetic Diagnostics Submarket: Revenue Forecast, 2011-2023

Table 3.11 Epigenetic Diagnostics Submarket: Drivers and Restraints, 2013-2023

Table 4.1 Epigenetic Therapies and Technologies Market by Country, 2011

Table 4.2 Epigenetic Therapies and Technologies in Developed Markets: Drivers and Restraints, 2013-2023

Table 4.3 Epigenetic Therapies and Technologies Market: Revenue Forecasts by Country, 2011-2023

Table 4.4 Epigenetic Therapies and Technologies in Emerging Markets: Drivers and Restraints, 2013-2023

8 of 12

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs